João Rafael de Oliveira Dias1, Renata Portella Nunes2, Raquel Goldhardt1. 1. Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, 900 NW 17 Street, Miami, FL, USA, 33136. 2. Federal University of São Paulo - Paulista Medical School, Department of Ophthalmology, Rua Botucatu 821, São Paulo-SP, Brazil, 04023-062.
Abstract
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS: Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME. Iluvien® releases fluocinolone for up to 36 months and is effective for the treatment of chronic DME. Retisert® (Bausch & Lomb, Rochester, NY) also releases fluocinolone, and is approved for chronic NIPU. Both Iluvien® and Retisert® are non-biodegradable devices and are highly associated with cataract and glaucoma. SUMMARY: Long-acting intraocular corticosteroid formulations offer a more predictable drug-release profile and reduced dosing frequency in comparison to conventional formulations of the same compounds but the risk-benefit ratio must be taken into consideration previous to the implantation of those devices.
PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of sustained-release corticosteroid devices for the treatment of cystoid macular edema (CME). RECENT FINDINGS:Ozurdex® is approved for the treatment of diabetic macular edema (DME), retinal vein occlusion related-CME and noninfectious posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 months making repeated intravitreal injections necessary for recurrent CME. Iluvien® releases fluocinolone for up to 36 months and is effective for the treatment of chronic DME. Retisert® (Bausch & Lomb, Rochester, NY) also releases fluocinolone, and is approved for chronic NIPU. Both Iluvien® and Retisert® are non-biodegradable devices and are highly associated with cataract and glaucoma. SUMMARY: Long-acting intraocular corticosteroid formulations offer a more predictable drug-release profile and reduced dosing frequency in comparison to conventional formulations of the same compounds but the risk-benefit ratio must be taken into consideration previous to the implantation of those devices.
Authors: Joan-En Chang-Lin; James A Burke; Qing Peng; Ton Lin; Werhner C Orilla; Corine R Ghosn; Kai-Ming Zhang; Baruch D Kuppermann; Michael R Robinson; Scott M Whitcup; Devin F Welty Journal: Invest Ophthalmol Vis Sci Date: 2011-06-28 Impact factor: 4.799
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li Journal: Ophthalmology Date: 2011-07-20 Impact factor: 12.079
Authors: Baruch D Kuppermann; Mark S Blumenkranz; Julia A Haller; George A Williams; David V Weinberg; Connie Chou; Scott M Whitcup Journal: Arch Ophthalmol Date: 2007-03
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Benjamin P Nicholson; Rishi P Singh; Jonathan E Sears; Careen Y Lowder; Peter K Kaiser Journal: Am J Ophthalmol Date: 2012-09-13 Impact factor: 5.258
Authors: João Heitor Marques; Ana Carolina Abreu; Nisa Silva; Angelina Meireles; Bernardete Pessoa; João Melo Beirão Journal: Int Med Case Rep J Date: 2021-02-26